The European Union Medical Device Regulation (EU MDR) has transformed the landscape for medical device manufacturers. Among the most critical changes is the requirement for robust Clinical Evaluation Reports (CERs) that demonstrate device safety and performance. As 2026 approaches, manufacturers and regulatory professionals face an evolving regulatory environment that demands precision, consistency, and strategic insight in CER preparation.
Understanding these requirements is no longer optional—it is central to market access in the EU. The stakes are high: insufficient or poorly structured CERs can delay approvals, invite scrutiny from notified bodies, or even jeopardize a device’s marketability.
The Foundation of a Compliant CER
A CER is more than a summary of clinical data; it is a structured document that links clinical evidence to device claims. The EU MDR emphasizes that clinical evaluation is a continuous process that integrates data from pre-market studies, post-market surveillance, and scientific literature.
By 2026, CERs must clearly demonstrate:
- The device’s conformity with general safety and performance requirements
- That clinical data are sufficient, relevant, and up to date
- That risk–benefit profiles are well substantiated for the intended population
Accuracy, transparency, and traceability are non-negotiable. Every statement must be supported by verifiable evidence, and any gaps or limitations in data need to be acknowledged explicitly.
The 2026 Updates: What Has Changed
Some key changes have been recommended by both the European Commission and the Notified Bodies within recent guidance documents. Areas of critical change include;
1.) An increased requirement for formal Post-Market Clinical Follow-Up (PMCF) to be reflected in the CER and integrated within the CER. PMCF will now have to be considered when developing CERs regarding how evidence from PMCF will demonstrate a device’s continuing safety and effectiveness in use within the community.
2.) A consistent approach is required between the information presented in the CER and the technical documentation that has been submitted as part of the application for CE Marking. All data that are presented in the CER must match against the information within the Risk Management File, Labels and Intended Use claims. Usually, any mismatches or inconsistencies in these areas will result in the CER being rejected or requesting additional information to clarify.
3.) Manufacturers should expect an increased level of scrutiny and assessment in relation to the equivalence claims made by device manufacturers. To support any equivalence claims regarding similar devices, device manufacturers should thoroughly justify any similarities/differences between the devices and how they will not affect device safety or clinical performance.
Structuring a CER for Maximum Impact
A compliant CER balances regulatory rigor with clarity. It should be organized logically: from device description and intended use to literature review, data appraisal, and conclusions on safety and performance. Each section must clearly link evidence to claims, presenting both supporting data and any limitations.
Importantly, CERs must reflect an ongoing clinical evaluation process rather than a static snapshot. Updates must be timely, reflecting new literature, clinical data, or post-market findings.
Common Pitfalls to Avoid
Even experienced teams can misstep. Common errors include insufficient justification of equivalence, incomplete integration of PMCF data, or failure to clearly articulate how evidence supports the benefit–risk assessment. Overly descriptive CERs without critical appraisal, or those that summarize literature without connecting it to device claims, are also frequently challenged.
Attention to these details is essential. CERs are not merely formalities—they are operational documents that demonstrate a manufacturer’s commitment to safety and compliance under EU MDR.
The Strategic Role of Professional CER Writing
At TMW, we combine scientific expertise with regulatory understanding to produce CERs that do more than meet documentation requirements. Our reports serve as operational tools that guide regulatory strategy, support notified body submissions, and ensure that clinical evidence clearly substantiates device claims. By integrating meticulous data appraisal with structured, readable reporting, we help manufacturers streamline CER preparation, reduce review cycles, and maintain compliance in a complex regulatory environment.
Professional writers trained in both clinical science and regulatory expectations are uniquely positioned to bridge the gap between raw clinical data and actionable, compliant documentation. Professional writers ensure that CERs not only satisfy MDR requirements but also function as reliable references across a device’s lifecycle.
Preparing for 2026 and Beyond
The EU MDR landscape will continue to evolve, and 2026 marks a critical checkpoint. Manufacturers who invest in strategic, high-quality CER preparation now will benefit from smoother regulatory submissions, enhanced credibility with notified bodies, and a reduced risk of delays or nonconformities.
CER writing under EU MDR is no longer just a technical exercise. It is a strategic element of regulatory planning, market access, and patient safety assurance. By approaching CER development with rigor, clarity, and foresight, companies can navigate EU MDR requirements confidently, ensuring that clinical evidence supports both compliance and clinical impact.
Learn more here.
